Geographical Features and Seroprevalence of Borrelia burgdorferi in Erzincan, Turkey

Çıkman, Aytekin; Aydın, Merve; Gülhan, Barış; Karakeçili, Faruk; Demirtaş, Levent; Kesik, Ozan Arif

doi:10.18502/jad.v12i4.356

Cited by 3 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A representative sample of healthy blood donors from the Tyrol region of Austria reported a seropositivity range of 1.5%–7.2% from samples confirmed by line blot ( 17 ). A regional study in Turkey among healthy volunteers revealed seropositivity of 4.1% by single-tier testing with ELISA and 2.2% confirmed by WB ( 18 ).…”

Section: Discussionmentioning

confidence: 99%

Systematic Review and Meta-analysis of Lyme Disease Data and Seropositivity for Borrelia burgdorferi, China, 2005‒2020

Stark¹,

Li²,

Zhang³

et al. 2022

Emerg. Infect. Dis.

View full text Add to dashboard Cite

Since its initial identification in 1986, Lyme disease has been clinically diagnosed in 29 provinces in China; however, national incidence data are lacking. To summarize Lyme disease seropositivity data among persons across China, we conducted a systematic literature review of Chinese- and English-language journal articles published during 2005‒2020. According to 72 estimates that measured IgG by using a diagnostic enzyme-linked assay (EIA) alone, the seropositivity point prevalence with a fixed-effects model was 9.1%. A more conservative 2-tier testing approach of EIA plus a confirmatory Western immunoblot (16 estimates) yielded seropositivity 1.8%. Seropositivity by EIA for high-risk exposure populations was 10.0% and for low-risk exposure populations was 4.5%; seropositivity was highest in the northeastern and western provinces. Our analysis confirms Lyme disease prevalence, measured by seropositivity, in many Chinese provinces and populations at risk. This information can be used to focus prevention measures in provinces where seropositivity is high.

show abstract

Section: Discussionmentioning

confidence: 99%

Systematic Review and Meta-analysis of Lyme Disease Data and Seropositivity for Borrelia burgdorferi, China, 2005‒2020

Stark¹,

Li²,

Zhang³

et al. 2022

Emerg. Infect. Dis.

View full text Add to dashboard Cite

show abstract

“…Eighteen articles reported seroprevalence of LB in four countries in Southern Europe (Güneş et al 2005 , Tomao et al 2005 , Krstić and Stajković 2007 , Bozkurt et al 2008 , Kaya et al 2008 , Uyanık et al 2009 , Di Renzi et al 2010 , Oteiza-Olaso et al 2011 , Aslan Başbulut et al 2012 , Jovanovic et al 2015 , Parlak et al 2015 , Bucak et al 2016 , Gazi et al 2016 , Cora et al 2017 , Akar et al 2019 , Cikman et al 2019 , Lledo et al 2019 , Barreiro-Hurle et al 2020 ). All studies reported subnational rather than country-wide estimates ( Table 3 ); 15 reported seroprevalence in groups at high risk of tick exposure based on occupation or residential area, and 11 reported on populations at low risk.…”

Section: Resultsmentioning

confidence: 99%

“…The weighted mean seroprevalence of LB in Southern Europe among studies that used (standard) two-tier testing strategies in general populations (Tomao et al 2005 , Kaya et al 2008 , Di Renzi et al 2010 , Aslan Başbulut et al 2012 , Jovanovic et al 2015 , Parlak et al 2015 , Bucak et al 2016 , Cora et al 2017 , Akar et al 2019 , Cikman et al 2019 , Barreiro-Hurle et al 2020 ) was 3.9% ( Table 7 ). The standard IgM and IgG weighted mean seroprevalence was 5.7% in high-risk groups versus 3.9% in low-risk groups.…”

Section: Resultsmentioning

confidence: 99%

“…In contrast, the trend was reversed in Turkey and the United Kingdom, where seroprevalence was consistently higher in women than in men. While one study reported a seroprevalence of 6.1% in male residents of a high-risk area versus 2.5% in women (ELISA+ELFA [enzyme-linked fluorescent assay] IgG) (Uyanık et al 2009 ), six other studies of residents in high-risk areas reported higher seroprevalence in women, with a difference between sexes of 0.2% to 6.0% (Aslan Başbulut et al 2012 , Parlak et al 2015 , Bucak et al 2016 , Cora et al 2017 , Akar et al 2019 , Cikman et al 2019 ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Seroprevalence of Lyme Borreliosis in Europe: Results from a Systematic Literature Review (2005–2020)

Burn¹,

Pilz

Vyse

et al. 2023

Vector-Borne and Zoonotic Diseases

View full text Add to dashboard Cite

Background: Lyme borreliosis (LB), a tick bite-transmitted infection caused by Borrelia burgdorferi sensu lato ( Bbsl ) complex spirochetes, is the most common tickborne disease in Europe. Studies in European countries have reported LB seroprevalence (prevalence of antibodies to Bbsl infection) and diagnostic strategies used for testing. We conducted a systematic literature review to summarize contemporary LB seroprevalence in Europe. Methods: PubMed, Embase, and CABI Direct (Global Health) databases were searched from 2005 to 2020 to identify studies reporting LB seroprevalence in European countries. Reported single-tier and two-tier test results were summarized; algorithms (standard or modified) were used to interpret final test results from studies that used two-tier testing. Results: The search yielded 61 articles from 22 European countries. Studies used a range of diagnostic testing methods and strategies (48% single-tier, 46% standard two-tier, and 6% modified two-tier). In 39 population-based studies, of which 14 were nationally representative, seroprevalence estimates ranged from 2.7% (Norway) to 20% (Finland). There was substantial heterogeneity among studies in terms of design, cohort types, periods sampled, sample sizes, and diagnostics, which limited cross-study comparisons. Nevertheless, among studies that reported seroprevalence in persons with greater exposure to ticks, LB seroprevalence was higher among these groups than in the general population (40.6% vs. 3.9%). Furthermore, among studies that used two-tier testing, general population LB seroprevalence was higher in Western Europe (13.6%) and Eastern Europe (11.1%) than in Northern Europe (4.2%) and Southern Europe (3.9%). Conclusion: Despite variations in LB seroprevalence between and within European subregions and countries, high seroprevalence was observed in certain geographic regions and particular risk groups, suggesting significant disease burden and supporting the need for improved, targeted public health interventions such as vaccination. Harmonized approaches to serologic testing and more nationally representative seroprevalence studies are needed to better understand the prevalence of Bbsl infection in Europe.

show abstract

Global seroprevalence and sociodemographic characteristics ofBorrelia burgdorferi sensu latoin human populations: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

IntroductionBorrelia burgdorferi sensu lato (Bb) infection, the most frequent tick-transmitted disease, is distributed worldwide. This study aimed to describe the global seroprevalence and sociodemographic characteristics of Bb in human populations.MethodsWe searched PubMed, Embase, Web of Science and other sources for relevant studies of all study designs through 30 December 2021 with the following keywords: ‘Borrelia burgdorferi sensu lato’ AND ‘infection rate’; and observational studies were included if the results of human Bb antibody seroprevalence surveys were reported, the laboratory serological detection method reported and be published in a peer-reviewed journal. We screened titles/abstracts and full texts of papers and appraised the risk of bias using the Cochrane Collaboration-endorsed Newcastle-Ottawa Quality Assessment Scale. Data were synthesised narratively, stratified by different types of outcomes. We also conducted random effects meta-analysis where we had a minimum of two studies with 95% CIs reported. The study protocol has been registered with PROSPERO (CRD42021261362).ResultsOf 4196 studies, 137 were eligible for full-text screening, and 89 (158 287 individuals) were included in meta-analyses. The reported estimated global Bb seroprevalence was 14.5% (95% CI 12.8% to 16.3%), and the top three regions of Bb seroprevalence were Central Europe (20.7%, 95% CI 13.8% to 28.6%), Eastern Asia (15.9%, 95% CI 6.6% to 28.3%) and Western Europe (13.5%, 95% CI 9.5% to 18.0%). Meta-regression analysis showed that after eliminating confounding risk factors, the methods lacked western blotting (WB) confirmation and increased the risk of false-positive Bb antibody detection compared with the methods using WB confirmation (OR 1.9, 95% CI 1.6 to 2.2). Other factors associated with Bb seropositivity include age ≥50 years (12.6%, 95% CI 8.0% to 18.1%), men (7.8%, 95% CI 4.6% to 11.9%), residence of rural area (8.4%, 95% CI 5.0% to 12.6%) and suffering tick bites (18.8%, 95% CI 10.1% to 29.4%).ConclusionThe reported estimated global Bb seropositivity is relatively high, with the top three regions as Central Europe, Western Europe and Eastern Asia. Using the WB to confirm Bb serological results could significantly improve the accuracy. More studies are needed to improve the accuracy of global Lyme borreliosis burden estimates.PROSPERO registration numberCRD42021261362.

show abstract

Geographical Features and Seroprevalence of Borrelia burgdorferi in Erzincan, Turkey

Cited by 3 publications

References 28 publications

Systematic Review and Meta-analysis of Lyme Disease Data and Seropositivity for Borrelia burgdorferi, China, 2005‒2020

Systematic Review and Meta-analysis of Lyme Disease Data and Seropositivity for Borrelia burgdorferi, China, 2005‒2020

Seroprevalence of Lyme Borreliosis in Europe: Results from a Systematic Literature Review (2005–2020)

Global seroprevalence and sociodemographic characteristics ofBorrelia burgdorferi sensu latoin human populations: a systematic review and meta-analysis

Contact Info

Product

Resources

About